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Abstract
Stimulation of N-methyl-D-aspartic acid receptors (NMDARs) and the resulting increase of nitric oxide (NO) production
are critical for fear memory formation. Following NMDAR activation, efficient production of NO requires linking the
95 kDa postsynaptic density protein (PSD95), a scaffolding protein to neuronal nitric oxide synthase (nNOS). A variety
of previously studied NMDAR antagonists and NOS inhibitors can disrupt fear conditioning, but they also affect many
other CNS functions such as motor activity, anxiety, and learning. We hypothesized that disrupting nNOS and PSD95
interaction in the amygdala, a critical site for fear memory formation, will reduce conditioned fear. Our results show
that systemic treatment with ZL006, a compound that disrupts PSD95/nNOS binding, attenuates fear memory
compared to its inactive isomer ZL007. Co-immunoprecipitation after fear conditioning showed a robust increase in
the amygdala PSD95/nNOS binding, which was blocked by systemic pre-administration of ZL006. Treatment of
amygdala slices with ZL006 also impaired long-term potentiation (LTP), a cellular signature of synaptic plasticity. Direct
intra-amygdala infusion of ZL006 also attenuated conditioned fear. Finally, unlike NMDAR antagonist MK-801, ZL006
does not affect locomotion, social interaction, object recognition memory, and spatial memory. These findings support
the hypothesis that disrupting the PSD95/nNOS interaction downstream of NMDARs selectively reduces fear memory,
and highlights PSD95/nNOS interaction as a novel target for fear-related disorders, such as posttraumatic stress
disorder.
Introduction
Normal fear learning and memory allow animals to
predict and avoid physical dangers and are therefore
essential to survival. However, following traumatic
experiences, these mechanisms can lead to symptoms of
syndromes such as posttraumatic stress disorder
(PTSD)1,2. PTSD is a severe psychiatric disorder in which
fear responses are likely sustained, generalized, and
inappropriately triggered out of context1,2. Pavlovian fear
conditioning is a well-established laboratory model of fear
learning that is often used to elucidate mechanism of fear
acquisition and extinction. In this paradigm, a neutral
event (a conditioned stimulus, (CS)), such as a tone, is
paired with an aversive event (an unconditioned stimulus
(US)), such as a footshock. Once learned, the CS acquires
the ability to evoke fear responses, such as freezing in
anticipation of the US3.
Pavlovian fear conditioning is known to be dependent
on the synaptic plasticity within the amygdala4,5 and is
mediated by excitatory neurotransmission acting through
N-methyl-D-aspartic acid receptors (NMDARs). A num-
ber of studies have demonstrated a critical role of
NMDARs in fear conditioning. For example, systemic and
CNS site-specific administration of NMDAR antagonists
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block fear acquisition when given before training6–9 and
impair fear expression when administered before fear
recall10,11. Unfortunately, despite this important role for
NMDARs in impairing fear formation, NMDAR antago-
nists have limited therapeutic potential due to their sig-
nificant adverse side-effect profiles12,13.
Stimulation of NMDARs activates a number of down-
stream signaling pathways. One such downstream effect
involves activation of the enzyme neuronal nitric oxide
synthase (nNOS) and the resulting production of the
signaling molecule nitric oxide (NO). nNOS is one of
three isoforms of NOS (the other isoforms being endo-
thelial NOS and inducible NOS) and is preferentially
expressed in neurons and functionally coupled to
NMDAR signaling14. There is strong evidence that acti-
vation of nNOS following NMDAR activation is a critical
component of fear memory formation15,16. Indeed, phar-
macological inhibition of enzyme activity and gene dele-
tion of nNOS have been shown to reduce fear. For
example, systemic and intra-amygdala administration of
NOS inhibitors reduce fear memories in multiple models
of fear conditioning17,18; mice with nNOS gene knockout
display impairments in both contextual and cued fear
learning19. Despite being downstream of NMDARs,
unfortunately, global inhibition of nNOS enzyme itself
cause undesired systemic effects, such as deficits in motor
functions20–22 and impairments in some other forms of
learning23–26. Therefore, similar to direct NMDAR
antagonism, therapeutic targeting of the downstream
nNOS enzyme is undesirable due to adverse effects.
Following NMDAR activation, nNOS binds to the
scaffolding protein postsynaptic density protein 95 kDa
(PSD95), and this is a required step for the efficient pro-
duction of NO14. Thus, selective disruption of the PSD95/
nNOS binding would allow a targeted approach to specific
reduction of NO production during high glutamate neu-
rotransmission state without affecting normal intracel-
lular nNOS functions. By not disrupting NMDAR-
dependent signaling pathways, this approach could cir-
cumvent the adverse effects associated with catalytic
nNOS inhibitors or NMDAR antagonists.
In the present study, we hypothesized that disrupting
PSD95/nNOS interaction would reduce fear, similar to the
NMDAR antagonists but with a better adverse effect profile.
To explore this hypothesis, we first examined the effect
of inhibition of PSD95/nNOS interaction on fear memory
formation by utilizing a small molecule disruptor of
PSD95/nNOS interaction ZL006 (4-(3,5-Dichloro-2-
hydroxy-benzylamino)-2-hydroxybenzoic acid). ZL006 is
a structural analog of the small molecule 2-((1H-benzo [d]
[1,2,3] triazol-5-ylamino) methyl)-4,6-dichlorophenol
(IC87201), the first reported disruptor of PSD95/nNOS
interaction. IC870201 was first identified in a high
throughput screen using the purified PDZ domains of
PSD95 and nNOS in a protein–protein binding assay27.
ZL006 was synthesized based on the molecular determi-
nants required for PSD95 and nNOS interaction28 and has
also been verified to selectively disrupt PSD95/nNOS
interaction without affecting PSD95 interactions with
other proteins28,29.
In a series of studies, we tested if systemic ZL006 given
shortly after a conditioning session would impair fear
memory consolidation in auditory fear conditioning
model, without affecting locomotor function, anxiety, and
other types of memory tests. Next, we studied the cellular
and molecular mechanisms mediating the effects of
ZL006 on fear memory formation. By using co-
immunoprecipitation (CO-IP) techniques, we tested if
fear conditioning results in significant increases in
PSD95/nNOS binding within the amygdala in a time
dependent manner, and if ZL006 disrupts this binding.
Utilizing brain slice electrophysiology, we tested whether
ZL006 disrupts LTP in the amygdala. Finally, to determine
if disruption of PSD95/nNOS binding within the amyg-
dala is sufficient to attenuate fear we directly administered
ZL006 within the amygdala to test if it would attenuate
conditioned fear. Our findings reported here support the
hypothesis that PSD95/nNOS interaction in the amygdala
is a key step in fear memory formation and may represent
a novel treatment target with a minimal adverse effect
profile for fear-related disorders, such as PTSD.
Materials and methods
Animals
Behavioral and biochemical experiments were per-
formed in adult male Sprague–Dawley rats (250–300 g,
Harlan, IN). The rats were housed singly in a
temperature-controlled room (22 °C) on a 12-hour light/
dark cycle (lights on at 0700 h) and left to acclimate to
housing for at least 3 days following delivery. Food and
water were provided ad libitum. The rats were handled
daily for a minimum of 3 days before any behavioral
experiment. Animal care procedures were conducted in
accordance with the NIH Guidelines for the Care and Use
of Laboratory Animals, 8th Edition and approved by the
IUPUI Institutional Animal Care and Use Committee.
Behavioral tests
Cued fear conditioning and memory expression testing
The day prior to conditioning, the rats were handled
and habituated to the conditioning box (25.5 × 25.5 ×
39.5 cm) for 10 minutes. The conditioning box was situ-
ated in a larger sound-attenuated chamber, which was
illuminated with a white 15-Lux light. A speaker in the
rear wall of the chamber was operating during all sessions
to provide white noise. The floor of the conditioning box
was constructed of parallel stainless-steel bars and con-
nected to a scrambled shock generator (Stoelting Co.,
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Wood Dale, IL, USA). Before each trial, the chamber and
the conditioning box were cleaned with 70% ethanol to
remove olfactory cues. On the conditioning day, the rats
were trained with three conditioning trials. Each trial
consisted of a 20 s, 4 kHz, 80 dB tone that co-terminated
with a 0.5 s, 0.8 mA footshock (inter-trial interval (ITI)
120 s). Rats were allowed to explore the chamber for 100 s
before conditioning began and remained in the chamber
for 60 s after the last trial. “Tone only” control rats were
placed in the conditioning box and exposed to 3 tones
(20 s, 4 kHz, 80 dB) without receiving shocks. Immediately
after fear conditioning, the animals received treatments of
drugs or vehicle. Testing for conditioned fear responses
(freezing) in rats were conducted 24 h following con-
ditioning. For this test, the rats were exposed to ten CS
tones (4 kHz, 80 dB, 20 s, ITI 60 s). Total time freezing
during the CS presentations were recorded and scored
manually by blinded raters, and this number was
expressed as a percentage of the total CS. Freezing was
defined as the absence of all movement except for normal
breathing.
Novel object recognition test
Novel object recognition test (NORT) was performed
according to the method described previously30, with
some minor modifications. The experiments were carried
out in an open-field box measuring 100 × 100 × 20 cm.
Prior to testing, the rats were allowed to explore the box
for 5 min per day for 3 consecutive days with no objects
present. Testing consisted of two 2min trials. During the
familiarization trial, a rat was placed in the box containing
two identical objects (plastic cylinders 6 cm in diameter
and 12 cm tall in white and red) in two opposite corners
and released against the center of the opposite wall with
its back to the objects. This was done to prevent coercion
to explore the objects31. The animals were regarded to be
exploring when they were facing, sniffing, or biting the
object with nose and/or forepaws. Immediately after
familiarization, the rats received intraperitoneal (i.p.)
injections of vehicle or drugs and were returned to its
home cage. After a waiting period of 3 h (ITI= 3 h), the
rat was placed in the box again and test trial was per-
formed. During this trial, a new object (plastic building
block in yellow or green, 7 × 3.5 × 9 cm) replaced one of
the familiar objects used in the familiarization trial. The
times spent in exploring each object during both trials
were recorded manually by using a stopwatch. The box
and the objects were cleaned with 70% of ethanol between
trials. Discrimination index (DI) used to measure the
discrimination behavior was calculated as the difference in
exploration time for the novel (TN) versus familiar objects
(TF), then dividing this value by the total time spent
exploring the two objects in the test trial. DI= TN− TF /
TN+TF
32.
Y-maze
Y-maze task was performed as previously described33.
Y-maze was constructed of Plexiglass with 3 arms each
measuring 34 × 8 × 14.5 cm. Visual cues were placed on
the walls of the maze. The maze was located in a room
with a light of 350 Lux brightness. Numerous distal cues
(tables, computers, chairs, and various small objects) were
around the Y-maze in the room and were kept constant
during the entire behavioral testing period. The three
arms were randomly designated: start arm, in which the
rats started to explore (always open), novel arm, which
was blocked during the 1st trial, but open during the 2nd
trial, and other arm (always open). The floors and walls of
the maze were cleaned with 70% ethanol to remove
olfactory cues. The Y-maze test consisted of two trials:
acquisition trial and test trial. In the acquisition trial, the
rat was allowed to explore only two arms (the start arm
and the other arm) of the maze for 10minutes. Injections
(i.p.) of vehicle or drugs were given just after acquisition
trial. After 1 h waiting period (ITI= 1 h), the test trial was
performed. In this trial, the novel arm was opened and the
rats were allowed 5minutes to explore all three arms. By
using a ceiling-mounted CCD camera, all trials were
recorded. Video recordings were later analyzed and the
number of entries and time spent in each arm were scored
manually for each rat.
Open-field test
The open-field (OF) apparatus consisted of a plexiglass
open-topped chamber (91.5 × 91.5 × 30.5 cm), a ceiling-
mounted CCD camera and a 25W red light bulb were
placed 2 meters above the center of the chamber. One
hour after vehicle or drug treatment, rats were gently
placed in the center and allowed to freely move 5minutes
while being tracked by an automated tracking system
(ANY-MAZE, Stoelting Co., Wood Dale, IL, USA). Total
distance traveled was used to measure locomotion activity
and results were normalized to vehicle controls.
Social interaction test
Social interaction (SI) test was performed 5min after
OF test in the same apparatus. The protocol used for the
SI test has been described previously34,35. In brief, the
“experimental” rat and the “partner” rat were simulta-
neously placed into the chamber for a 5 min test. The
“partner” rat was age-, sex- and weight-matched to the
“experimental” rat. All tests were video recorded from
above and then manually scored using using ODlog for
Mac OS X version 2.6.1. Social interaction time (in s) per
pair of rats was measured as time spent by the “experi-
mental” rat engaging in non-aggressive physical investi-
gation of the “partner” rat; defined by the “experimental”
rat sniffing, climbing over and crawling under the
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“partner” rat, mutual grooming, genital investigation, or
following and walking around the partner.
Randomization and blinding
All behavioral tests performed on each animal were
determined randomly by an experimenter. No explicit
randomization algorithm was used. In the behavioral tests
where manual scoring was required, the tests were video
recorded and scored by an experimenter who was blinded
to the treatments.
Co-immunoprecipitation
Following behavioral training and sacrifice by decap-
itation under isoflurane, the brains were removed and
immediately frozen in iso-pentane (Fisher Scientific,
Rockford, IL, USA) on dry ice and were stored at −80 °C
until processed. Punches containing the BLA were
obtained using a 1 mm diameter Harris micro-punch
(Electron Microscopy Sciences, Hatfield, PA, USA) from
300-μm thick sections taken on a freezing microtome (see
Supplementary Fig. S1 for locations of micropunches).
The punches were immediately homogenized in 100 μl of
ice-cold lysis buffer (25 mM Tris, 150mM NaCl, 1 mM
EDTA, 1% NP-40, 5% glycerol, PH 7.4) supplemented
with Halt protease inhibitor cocktail and Halt phospha-
tase inhibitor cocktail (Thermo Scientific, Rockford, IL,
USA). After lysis on ice for 15min with periodic mixing,
samples were centrifuged at 13,000× g/4 °C for 15min.
The supernatants were pre-incubated for 1 h at 4 °C with
25 μl of Control Agarose Resin (Thermo Scientific) and
then centrifuged to remove proteins that adhered non-
specifically to the resin. nNOS antibody (mouse antibody
to nNOS, A-11, Santa Cruz Biotechnology, Dallas, TX,
USA) at 2 μg per 100 μg of total protein or normal mouse
IgG (Santa Cruz Biotechnology) was added to the super-
natant and incubated overnight at 4 °C. Protein A/G
Agarose (Thermo Scientific) was then added to the anti-
body/lysate sample and incubated at 4 °C for 1 h. Immune
complexes were isolated by centrifugation, washed 5 times
with lysis buffer, and bound proteins were eluted by
heating at 95 °C in loading buffer for 10min for immu-
noblotting. Samples were loaded to 10% acrylamide
denaturing gels (SDS-PAGE) and transferred to nitro-
cellulose membranes (Amersham, Pittsburgh, PA, USA).
Nitrocellulose membranes were blocked with 5% milk in
TBST buffer (50 mM Tris-Cl, pH 7.6; 150mM NaCl; 0.1%
Tween 20) and then incubated with mouse nNOS anti-
body (1:1000, Santa Cruz Biotechnology), mouse PSD95
antibody (1:2000, Invitrogen, Rockford, IL, USA), and
mouse β-actin antibody (1:10000, Santa Cruz Bio-
technology) and detected using goat anti-mouse-HRP
(Santa Cruz Biotechnology) at 1: 2,000 for nNOS, 1: 5000
for PSD95, 1: 10000 for β-actin. Detection of protein band
signals was achieved by adding chemoluminescent buffer
(Millipore, Billerica, MA, USA) to the blots. Films were
scanned and densitometry was performed using ImageJ
1.48 software.
Surgery
Prior to surgery, the rats were anesthetized by placing
them in a closed plastic box connected to an Isoflurane
system (MGX Research Machine, Vetamac, Rossville, IN,
USA). The animals were then removed from the box and
placed on a stereotaxic instrument (Kopf Instruments,
Tujunga, CA, USA). Anesthesia was maintained via a nose
cone, which allowed for constant flow of isoflurane (2–3%
by volume) throughout the surgery. An incision was made
in the scalp and the skull was cleaned and dried. Two
stainless-steel guide cannulas (26 gauge, Plastics One,
Roanoke, VA, USA) were implanted bilaterally into the
basolateral nucleus of the amygdala (BLA) using the fol-
lowing coordinates, anterior, −2.3 mm; lateral, ±4.9 mm;
and ventral, −7.4 mm, according to the brain atlas of
Paxinos and Watson (fifth edition). The guide cannulas
were secured into place using three 2.4 mm screws
anchored into the skull along with cranioplastic cement.
Dummy cannulas (Plastics One, Roanoke, VA, USA) with
lengths matching the guide cannulas were placed inside
the guide cannulas to prevent occlusions. Following sur-
gery, all rats were given pain medication (buprenorphine,
Indiana University School of Medicine Laboratory Animal
Resources) and allowed to recover for 7 days before
behavioral testing. During recovery, the rats were gently
handled every day for a minimum of 2 min.
Intracranial injections
To execute local infusions into BLA, the dummy can-
nulas were quickly removed from the guide cannulas and
were replaced by internal cannulas (extended 1.0 mm
beyond the guide cannulas, Plastics One, Roanoke, VA,
USA). The internal cannulas were connected via poly-
ethylene tubing to 10 µl microsyringes (Hamilton, Reno,
NV, USA). An injection volume of 0.25 µl was delivered
using a Harvard PHD 2000 (Harvard Apparatus, Inc.,
South Natick, MA, USA) syringe pump over the course of
2.5 min. Internal cannulas remained in the guide cannulas
for 1 min after druginfusion to allow diffusion of the drug
from the tip. At the end of the microinfusion experiment,
the rats were enuthanized by an overdose of isoflurane
and perfused with 4% Paraformaldehyde (PFA). Neutral
red staining and light microscopy were used to verify the
location of the cannula tips within the BLA (see Supple-
mentary Fig. S3 for details).
Slice electrophysiology
Electrophysiological experiments in amygdala slices
were conducted as previously described36. The rats were
anesthetized with 3–5% isoflurane and decapitated. The
Li et al. Translational Psychiatry  (2018) 8:155 Page 4 of 13
brains were rapidly removed and placed in ice-cold oxy-
genated artificial cerebrospinal fluid (ACSF) containing in
mM: 130 NaCl, 3.5 KCl, 1.1 KH2PO4, 1.3 MgCl2, 2.5
CaCl2, 30 NaHCO3, 10 glucose (315 mOsm, 7.4 pH), and
coronal slices (350 µM) were prepared containing the
BLA (BLA, ~−2.3 mm from bregma). Slices were then
subjected to a recovery protocol to improve cell viability
which included thirty minute incubations in 30 °C ACSF
and then room temperature ACSF prior to recording.
Oxygenated ACSF, heated to 30 °C, was perfused at a rate
of 2–3ml per minute during recording on the stage of a
Nikon E600FN Eclipse microscope (Nikon Instruments,
Melville, NY, USA). Borosilicate glass electrodes (WPI,
Sarasota, FL, USA) with resistances between 3 and 6MΩ
were filled with potassium gluconate based recording
solution containing in mM: 130 K-Gluconate, 3 KCl, 3
MgCl2, 5 phosphocreatine, 2 K-ATP, 0.2 Na-GTP, 10
HEPES, 0.05 picrotoxin (Sigma, St. Louis, MO, USA), and
whole-cell patch clamp responses in current clamp mode
were recorded by standard techniques using Multi-
clamp700B amplifier and Digidata1440 digitizer (Mole-
cular Devices, Sunnyvale, CA, USA). BLA pyramidal
neurons were identified by their morphology and further
validated by basic electrophysiological property of input
resistance (~35MΩ)37. Cell-holding potential was main-
tained at −70 mV and electrically evoked responses were
produced by Master8 pulse stimulator (A.M.P.I, Jer-
usalem, Israel) as previously described38. Compounds
were added directly to the ACSF and included ZL-family
compounds at 10 µM and GABA-B receptor antagonist
CGP52432 (Tocris, Minneapolis, MN, USA) at 1 µM.
Evoked EPSPs were generated via electrical stimulation
with a concentric, platinum/iridium, bipolar electrode
(FHC, Bowdoin, ME, USA) placed ~1mm from the
recorded cell, within the BLA and directly medial to the
external capsule. Baseline evoked EPSP responses were
recorded once per minute for 10 minutes at the beginning
of each experiment to verify consistent cell properties of
resistance and evoked response amplitude. For conditions
where ZL-family compounds were tested, an additional
10 minutes of baseline responses were recorded to
determine if the compound had any effect on evoked
response amplitude. Current injected for evoked respon-
ses was adjusted for each individual cell to produce
roughly 5 mV depolarization and reliably allowed detec-
tion of potentiation without depolarization to action
potential threshold. The average current injected to
achieve this depolarization was 290 pA. For cells that
demonstrate a consistent baseline, 100 Hz high frequency
stimulation (HFS) was applied to induce potentiation of
evoked responses as previously described39. This combi-
nation of depolarization and evoked stimulation produces
action potentials and when preformed in 20 one-second
bursts spaced 20 seconds apart is able to produce short-
term and LTP. Cells that did not induce short-term
potentiation were omitted.
Drugs and chemicals
ZL006 and MK-801 were purchased from Sigma
Aldrich (St. Louis, MO, USA). ZL007 was synthesized in
the laboratory of Dr. Ganesh Thakur at the Northeastern
University Center for Drug Discovery (Boston, MA, USA).
In the behavioral tests with i.p. injections, ZL006 and
ZL007 were dissolved in a vehicle of 10% DMSO (Sigma
Aldrich, St. Louis, MO, USA), with the remaining 90%
consisting of 100% ethanol (Fisher Scientific, Rockford, IL,
USA), emulphor (Alkamuls EL-620, Solvay, Brussels,
Belgium) and sterilized saline at a ratio of 1:1:8, respec-
tively. MK-801 was dissolved in sterilized saline. Injection
volume was 1 ml/kg and control animals were injected
with an equal volume of vehicle. For intra-amygdala
infusion, ZL006 was diluted from ZL006 stock solution
(dissolved in 100% DMSO) at 1:1000 in ACSF to yield a
final concentration of 10 µM.
Statistical analysis
Data were expressed as group mean with SEM. Sample
size was determined based on power calculations from
previous reports and/or our pilot studies. A two-way
repeated ANOVA was used to compare the effects of
treatment and time across the trials of fear conditioning
and memory expression tests, followed by post hoc
Fisher’s LSD tests. For multiple group comparisons, sta-
tistical differences were calculated by one-way ANOVA
followed by post hoc Fisher’s LSD tests.
Greenhouse–Geisser correction was applied when the
assumption of sphericity was violated. Data from slice
electrophysiology was analyzed by two-way ANOVA
comparing differences between treatments and over time.
Statistical significance was determined using Fisher’s LSD
multiple comparisons post hoc analysis. Values of P < 0.05
were considered significant.
Experimental procedures
Effects of systemic disruption of PSD95/nNOS interactions on
consolidation of auditory Pavlovian fear conditioning
To investigate if disruption of PSD95/nNOS binding
can impair conditioned fear, we treated rats with i.p.
injections of different doses of a small molecule inhibitor
of PSD95/nNOS interaction, ZL006 (1 mg/kg, 3 mg/kg, or
10mg/kg) immediately after training and tested fear
expression 24 h later (Fig. 1a). In these tests, we utilized a
control group of animals that received the same con-
ditioning procedures but without shock pairing (“Tone
only”). During the conditioning, shocked animals who
acquire fear would freeze during the presentation of tone
whereas “Tone only” controls would not freeze to the
tone.
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Effects of disrupting PSD95/nNOS on motor activity and
short-term memory
While NMDA antagonists like MK-801 and ketamine
are also highly effective in blocking fear conditioning, they
have significant acute motor and memory effects. There-
fore, we tested motor activity and short-term memory
effects of disrupting PSD95-nNOS interactions using the
dose of ZL006 that were effective in reducing fear mem-
ory (10 mg/kg), comparing it to similarly effective doses of
MK-801 (0.1 mg/kg).
Determining fear-conditioning-induced increases in PSD95/
nNOS binding in the amygdala, and the effects of pre-
administration of ZL006
We sought to characterize the molecular mechanisms
that underlie ZL006 action in attenuating memory for-
mation of conditioned fear. Amygdala, and specifically,
the BLA, is a critical neural locus for conditioned fear
learning and expression2,40,41. We hypothesized that if
PSD95/nNOS interaction is a critical downstream event
from NMDAR signaling during fear conditioning, then an
increased binding of these two proteins will be seen in the
BLA following fear acquisition, and that this binding can
be prevented by pre-administration of ZL006. To test this
hypothesis, animals that received fear conditioning were
sacrificed and the levels of PSD95/nNOS binding in the
BLA were quantified with CO-IP with nNOS antibody
followed by immunoblotting with nNOS and PSD95
antibodies. This CO-IP experiments after fear condition-
ing was repeated for several time points following fear
conditioning ranging from 0.5 to 6 h. As a control, a
separate group of rats received the same procedure but
without shock pairing were sacrificed 0.5 h after no shock
training (“Tone only”) (Fig. 3a).
Testing the effects of disrupting PSD95/nNOS binding on LTP
of BLA neurons
Alterations of synaptic plasticity in the BLA have been
thought to promote the induction and expression of fear
memory5,42. To further investigate the mechanisms of
Fig. 1 Systemic disruption of PSD95/nNOS interaction and inhibition of NMDAR impaired consolidation of auditory Pavlovian fear
conditioning. a Schematic of the behavioral protocol. Immediately after fear conditioning, rats were given i.p. injections of indicated treatments. The
retention of conditioned fear memory was tested 24 h later. b The five groups of animals that had tone/shock pairings showed normal cued fear
acquisition (Trial: F2, 56= 299.4, P < 0.0001). In the fear expression test, 10 mg/kg ZL006 treated animals (n= 8) displayed significantly decreased
freezing responses when compared with vehicle controls (n= 7) (post hoc test: t= 3.77, DF= 28, P < 0.001). ### P < 0.001 ZL006 10 mg/kg vs.
vehicle; Groups with lower doses of ZL006 (1 mg/kg and 3mg/kg, n= 6) and ZL007 group (n= 6) showed similar levels of freezing during fear
expression compared to the vehicle group (P > 0.05). Rats in “Tone only” group (n= 7) did not freeze to the CS in neither fear training nor fear
expression test. c Both vehicle (n= 7) and MK-801 (n= 7) treated animals showed normal cued fear acquisition (Trial: F2, 24= 59.62, P < 0.0001).
However, MK-801 treated animals showed significantly decreased freezing responses in fear expression test (Treatment: F1, 12= 8.550, P < 0.05). *P <
0.05, **P < 0.01 relative to vehicle group
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ZL006 action in attenuating memory formation of con-
ditioned fear, we examined whether local application of
PSD95/nNOS binding inhibitor ZL006 would alter
synaptic plasticity in the BLA slice preparations. We used
whole-cell patch clamp technique and HFS protocol to
induce LTP of BLA projection neurons and 10 µM ZL006
treated neurons were compared to neurons treated with
vehicle or inactive isomer 10 µM ZL007.
Effects of disrupting PSD95/nNOS binding directly in the
amygdala on fear conditioning
Finally, we asked if direct injections of PSD95/nNOS
binding inhibitor ZL006 into BLA could impair memory
formation of conditioned fear. The rats were implanted
with guide cannulas into the BLA and underwent fear
conditioning training seven days after surgery. Intra-BLA
infusions of vehicle or 10 µM ZL006 were given imme-
diately after training and rats were tested for expression of
fear memory 24 h after training (Fig. 5a).
Results
Disruption of PSD95/nNOS interactions with ZL006 impairs
fear conditioning
When given systemically immediately following fear
conditioning sessions, we found that vehicle controls
showed robust conditioned fear responses during the test-
ing sessions 24 h later, whereas 10mg/kg ZL006 treated
group had significantly reduced conditioned freezing
(multiple comparisons post hoc test, P < 0.05) (Fig. 1a, b).
Lower doses of ZL006 failed to reduce freezing responses in
this test. ZL007, an inactive analog of ZL006 was utilized as
a negative control in these tests. We found that animals
treated with 10mg/kg ZL007 did not show differences in
freezing responses when compared with vehicle controls
(Fig. 1b). Similar to ZL006 (10mg/kg), post-training i.p.
administration of NMDAR antagonist MK-801 (0.1mg/kg)
also significantly reduced freezing responses in the fear
expression test (Fig. 1a, c). Collectively, these findings sug-
gest that similar to NMDAR antagonist MK-801, disruption
of PSD95/nNOS binding can impair memory formation of
auditory Pavlovian fear conditioning.
ZL006 does not cause behavioral and memory disruptions
seen with NMDAR antagonism
We tested motor activity and short-term memory
effects of either blocking NMDA receptors or disrupting
PSD95-nNOS interactions, utilizing MK-801 (0.1 mg/kg i.
p.) or ZL006 (10 mg/kg i.p.), respectively, both at doses
that were equally effective in reducing fear memory. In the
OF test, the total distances covered in the open-field arena
after ZL006 treatments were comparable to the vehicle
group, whereas the total distance was significantly higher
in the MK-801 group (Fig. 2a). In the SI test, while ZL006
treated animals showed comparable interaction activity
with the vehicle controls, MK-801 treated animals dis-
played significantly reduced interaction activity (Fig. 2b).
In the NORT, DI demonstrated that ZL006 did not cause
deficits in the discrimination behavior when compared
with the vehicle controls, whereas rats treated with MK-
801 were unable to discriminate between the familiar and
the novel object (Fig. 2c). To test the spatial memory, Y-
maze with a two-trial test was utilized. Here, we observed
that vehicle controls and ZL006 treated rats displayed an
intact spatial recognition memory: these animals had a
higher frequency of visits (Vehicle: F2, 15= 4.892, P < 0.05;
ZL006: F2, 15= 6.628, P < 0.01) and longer durations
(Vehicle: F2, 15= 10.56, P < 0.01; ZL006: F2, 15= 7.965, P
< 0.01) within the novel arm than in the other arms.
However, the rats treated with MK-801 demonstrated an
impaired spatial recognition memory: they visited the
novel arm less than the other arms (F2, 15= 3.896, P <
0.05) and spent equal time in all of the three arms (F2, 15
= 0.3418, P > 0.05) (Fig. 2d). Collectively, our findings
demonstrate that disrupting PSD95-nNOS interaction is
devoid of some of the acute effects seen with NMDA
receptor antagonists, such as locomotor hyperactivity,
reduced social interaction, and disrupted performances in
object recognition and spatial recognition.
Fear conditioning induces a robust increase in the
amygdala PSD95/nNOS binding, which is blocked by pre-
administration of ZL006
In the first experiment, we tested if conditioned fear
training would increase PSD95-nNOS interactions in the
amygdala, and determined the time course for the inter-
action. We observed a significantly increased association
between PSD95 and nNOS at 1 h and 2 h after training,
when compared with “Tone only” controls (Fig. 3a, b).
The increased association between PSD95 and nNOS
recovered to baseline level by 6 h. All of the fear condi-
tioned groups showed similar acquisition of conditioned
fear (Supplementary Fig. S2a). Next we tested if the fear-
conditioning-induced increases in PSD95/nNOS complex
could be blocked by a pretreatment of ZL006. Two groups
of rats received fear conditioning and were treated with an
i.p. injection of either vehicle or ZL006 10mg/kg imme-
diately after conditioning. The levels of PSD95/nNOS
complex in the BLA were quantified with CO-IP 1 h after
conditioning, the time point when the PSD95/nNOS
interaction peaked after acquisition of conditioned fear as
previously noted (Fig. 3c). Once again, the level of PSD95/
nNOS complex was significantly increased at 1 h after
conditioning and this robust increase was blocked in the
rats treated with ZL006 (Fig. 3d). All three groups also
showed comparable conditioned freezing response during
acquisition (Supplementary Fig. S2b). Taken together,
these findings suggest that fear conditioning causes a
robust increase in the amygdala PSD95/nNOS binding,
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and that administration of ZL006 can effectively block this
increased PSD95/nNOS binding.
Disrupting PSD95/nNOS interaction prevents LTP of BLA
neurons
At resting conditions, perfusion of BLA slice prepara-
tions with ZL006 had no significant effects on evoked
excitatory postsynaptic potentials or input resistance
during patch clamp studies of amygdala neurons in slice
preparations. After establishing baseline responses to
positive current injection, HFS-induced LTP was
observed in vehicle and ZL007 control conditions
(183.4 ± 7.8 and 185.6 ± 8.4 percent of baseline at 1 h,
respectively). Following short-term potentiation, evoked
EPSP responses of ZL006 treated BLA neurons gradually
returned to baseline levels (98.0 ± 3.9 percent of baseline
at 1 h) and were statistically divergent from control
responses at all time points t > 16min (Fig. 4a, b). Nega-
tive current was injected once per minute to test whether
changes to evoked EPSP amplitude resulted from changes
to membrane resistance and revealed no differences
between conditions or over time (Fig. 4c). Collectively,
these observations indicate that disrupting PSD95/nNOS
binding by ZL006 impairs LTP, a cellular signature of
synaptic plasticity in BLA neurons.
Inhibiting PSD95/nNOS binding directly in the amygdala
reduces conditioned fear
During conditioning, no difference was found in the
freezing response between the pre-assigned vehicle and
ZL006 group (Fig. 5b). However, in the fear expression test,
animals received intra-BLA infusions of ZL006 showed
significantly reduced freezing responses compared with
vehicle controls (Fig. 5c). Thus, similar to systemic disrup-
tion of PSD95/nNOS binding, intra-BLA administration of
small molecule inhibitor ZL006 immediately after training
impairs memory formation of auditory fear conditioning. In
three additional animals, the injection sites were anterior to
the BLA, and ZL006 injections at these sites had no sig-
nificant effects (data not shown).
Discussion
The findings reported here clearly support that dis-
rupting PSD95-nNOS interaction with ZL006 given
shortly after an auditory cue-induced conditioning session
impairs fear memory consolidation. This is consistent
Fig. 2 Disruption of PSD95/nNOS with ZL006 does not have the non-specific behavioral effects seen with NMDARs antagonist MK-801. a
Animals received i.p. injections 1 h prior to the OF Test. MK-801-treated animals displayed increased locomotor activity (F2, 25= 7.562, P < 0.01). SI test
b was performed 5min after OF test. MK-801-treated animals showed decreased social activity (F2, 25= 9.548, P < 0.001). n= 14, 6, and 8 for control,
ZL006 and MK801, respectively. c In NORT, animals received i.p. injections immediately after the familiarization trial and the testing trial was
conducted after a 3 h ITI. Discrimination index expressed by different groups of rats during the testing trial showed that MK-801 treated rats displayed
deficits in the discrimination behavioral (n= 11, 9, and 9 for control, ZL006 and MK801, respectively; F2, 26= 5.993, P < 0.01). d In the Y-maze test, the
animals received i.p. injections immediately after the familiarization trial and the testing trial was conducted after a 1 h ITI. n= 6 for each group. Left:
rats in the vehicle and ZL006 treated groups visited novel arm more than the other two arms (P < 0.05); however, animals treated with MK-801 visited
novel arm less that the other arms (P < 0.05); Right: controls and ZL006 treated rats spent more time in the novel arm than the other arms (P < 0.01);
no arm difference was found in the rats treated with MK-801 (P > 0.05). *P < 0.05, **P < 0.01; ITI inter-trial interval, OF open field, SI social interaction,
NORT novel object recognition
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with a recent study that reported that ZL006 pretreatment
blocks contextual fear conditioning43. Similar to ZL006,
disruption of conditioned fear was also observed with
NMDA receptor antagonist MK-801. However, unlike the
NMDA antagonist, ZL006 does not appear to affect
locomotor function, social interaction, and other short-
term memory tests. By using co-immunoprecipitation
techniques, we also demonstrate that fear conditioning
results in significant increases in PSD95/nNOS binding
within the amygdala in a time dependent manner, and
that ZL006 pretreatment disrupts this binding. Utilizing
brain slice electrophysiology, we determined that ZL006
disrupts LTP in the amygdala. Finally, disruption of
PSD95/nNOS binding directly within the amygdala was
able to attenuate fear. Thus, PSD95-nNOS binding
appears to be a key molecular step in regulating synaptic
strengthening, LTP and fear memory formation within
the amygdala. Disruption of PSD95/nNOS interaction
could therefore be a more targeted approach to reducing
fear consolidation in the amygdala circuits during high
neurotransmission state without affecting other NMDAR-
dependent signaling pathways.
An important observation in our study was that ZL006,
unlike MK-801, selectively disrupted fear conditioning
without affecting short-term memory tests and motor
responses. We found that i.p. injection of MK-801 at the
dose effective in reducing fear (0.1 mg/kg) caused hyper-
locomotion in rats in an OF test. Impaired locomotor
function was also reported in animals treated with 7-Ni,
an inhibitor of NOS21,22. In a SI test, we observed
Fig. 3 Fear conditioning induces a robust increase in amygdala PSD95/nNOS binding, which is prevented by pretreatment of ZL006. a
Schematic of the behavioral protocol. Rats were habituated to the conditioning box, fear conditioned with 3 tone/shock pairings and sacrificed either
0.5, 1, 2, or 6 h following conditioning. The “Tone only” group did not receive shock and were sacrificed 0.5 h after non-shock training. b Protein
extracts from BLA were immunoprecipitated with nNOS antibody and immunoblotted with PSD95 antibody (top, representative blots). Levels of
PSD95/nNOS ratio were expressed as a percentage of those in “Tone only” controls (n= 3 or 4, F4, 14= 3.526, P < 0.05) (bottom). *P < 0.05, **P < 0.01
relative to “Tone only” group; # P < 0.05 relative to 1 h group. c Schematic of the behavioral protocol. Immediately after fear conditioning, rats
received i.p. injections of either vehicle or 10 mg/kg ZL006 and were sacrificed 1 h after fear conditioning. d Protein extracts from BLA were
immunoprecipitated with nNOS antibody and immunoblotted with PSD95 antibody (top, representative blots). Levels of PSD95/nNOS ratio were
expressed as a percentage of those in “Tone only” controls (n= 5, F2, 12= 5.895, P < 0.05) (bottom). **P < 0.01 relative to “Tone only” group; # P < 0.05
relative to vehicle group
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reduction of social behaviors with MK-801, which was in
agreement with a previous study demonstrating a defec-
tive social interaction by MK-801 in a dose-dependent
manner44. 7-Ni has been reported to possess anxiolytic
effect in the SI test45, our experiment indicated no
anxiolytic effect of ZL006.
Due to numerous studies demonstrating learning defi-
cits caused by NMDAR antagonists and NOS inhibitors in
multiple hippocampal memory tests, we investigated
whether ZL006 affects hippocampus-dependent
memories by utilizing NORT and Y-maze test. Consistent
with previous research46–48, we found that post-training i.
p. administration of MK-801 disrupted animals’ perfor-
mance in both of the tests. However, ZL006 did not cause
deficits in these tests. Overall, our results are consistent
with the findings that ZL006 does not affect motor
function29,49, spatial memory28, or source memory49 in
rodents. This lack of acute motor and cognitive effects of
ZL006 has significant clinical implications. NMDA
antagonists, specifically ketamine, appears to be an
effective treatment for reducing PTSD symptoms50.
However, a major limitation of drugs like ketamine is their
acute effects on cognition and mental status that could
last several hours to days after an initial administration. A
novel target that could have the same magnitude of effects
in reducing conditioned fear but without such acute CNS
adverse effects could address an important barrier to
developing novel compounds as treatment options for
fear disorders.
Our current data showed that disruption of PSD95/
nNOS interaction by ZL006 selectively impairs fear
memory through an amygdala-dependent mechanism
without significantly influencing non-fear, acute mem-
ories as measured by NORT and Y-maze behaviors. This
selectivity of ZL006 in disrupting amygdala-based fear
learning tests but not primarily hippocampus-based spa-
tial learning tasks is interesting. In agreement with our
observation with ZL006, a previous study demonstrated
that performance in NORT and water maze tests
remained intact after administering TRIM, a selective
nNOS but not an eNOS inhibitor26. However, these
hippocampus-dependent learning mechanism became
disrupted when both nNOS and eNOS were inhibited
with 7-Ni, a non-selective NOS inhibitor26. Similarly,
another electrophysiological study demonstrated that LTP
in the CA1 region of the hippocampus from nNOS
knockout mice and eNOS knockout mice were normal,
but LTP was severely disrupted in nNOS and eNOS
double mutants51. One possible explanation for the lack
of ZL006 effects on these acute spatial or object memory
tests is that in the hippocampus, eNOS activation may be
compensating for the disruption of nNOS activity.
Consolidation of fear is the process where stimulus-fear
association via CS/US pairing is stabilized into a persistent
memory. This process is generally thought to require gene
transcription and translation of post- and/or pre-synaptic
proteins that result in long-term plasticity within the
neural network involved in fear3. Previous studies have
suggested that the NO signaling pathway plays a critical
role in facilitating this long-term plasticity. For example,
biochemical and behavioral studies have shown that intra-
amygdala infusion of the NOS inhibitor 7-Ni or PKG (a
downstream effector of NO) inhibitor Rp-8-Br-PET-
cGMPS significantly reduced the fear-conditioning-
Fig. 4 PSD95/nNOS binding inhibitor ZL006 prevents HFS-
induced LTP of BLA neurons. a Representative traces from individual
experiments before and 1 h after HFS b LTP produced in the ZL006
treated cells following HFS was significantly depressed compared with
vehicle and ZL007 conditions (Treatment: F2, 1243= 434.0, P < 0.0001).
Multiple comparisons post hoc analysis revealed that EPSP responses
in cells treated with ZL006 were different from cells treated with
vehicle or ZL007 at all time point t > 16minutes (P < 0.05) (n= 10, 6
and 6 for vehicle, ZL007 and ZL006, respectively). c Membrane
resistance was not different when compared between groups or over
time (n= 8, 6, and 5 for vehicle, ZL007 and ZL006, respectively). Arrow
indicates initiation of high frequency stimulation (HFS)
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induced expression of postsynaptic GluR1, pre-synaptic
synaptophysin, and synapsin in the amygdala16; animals
receiving infusions of the above drugs also exhibited
impaired conditioned fear memory15,17. Previous studies
have also revealed physical association of nNOS with a
variety of regulatory proteins and these associations are
critical in regulating nNOS activity and the resulting NO
production. PSD95 is one of the regulatory proteins that
interact directly with the PDZ domain of nNOS52. In the
present study, we first investigated if PSD95/nNOS
interaction is induced by fear conditioning utilizing a CO-
IP assay. We found that amygdalar PSD95/nNOS inter-
action began to increase by 30min after fear conditioning,
peaked at 1 h, and remained increased until 6 h after
conditioning. Importantly, i.p. administration of ZL006
immediately following fear conditioning prevented the
enhancement of PSD95/nNOS interaction measured 1 h
after conditioning. The CO-IP results collectively suggest
an involvement of increased PSD95/nNOS interaction
during the consolidation phase of fear memory, and that
disruption of PSD95/nNOS interaction by ZL006 blocks
this process. Based on our findings with CO-IP assay and
LTP study, we finally tested if direct disruption of PSD95/
nNOS interaction in the amygdala could impair the
consolidation of fear memory. We found that intra-BLA
infusion of ZL006 at an effective dose for reducing LTP
also impaired fear memory expression when administered
immediately after conditioning.
These results are consistent with the idea that the
amygdala may be the neural locus mediating ZL006 action
on auditory fear conditioned responses. However, the
degree to which intra-BLA ZL006 injections were able
disrupt the consolidation of fear was much lower than
that observed when we administered the same drug sys-
temically. This suggests the possibility that in addition to
amygdala, other brain regions might also be involved in
mediating the effects of ZL006 on conditioned fear. A
recent study reported that ZL006 acting through the
hippocampus could disrupt contextual fear memories43.
Thus, hippocampus appears to be another key region
where PSD95-nNOS interaction is critical for certain
subtypes of fear responses. The hippocampus is also
implicated in other aspects of conditioned fear responses,
including fear generalization and fear extinction. Simi-
larly, regions of the prefrontal cortex are also important in
the consolidation and extinction of conditioned fear53 and
may include interactions between BDNF and NO54. Thus,
it would be important to study the role of PSD95-nNOS
interactions within these critical structures in regulating
various aspects of conditioned fear including fear acqui-
sition, extinction learning and extinction memory.
In addition to conditioned fear, this mechanism is also
implicated in other neuropsychiatric and neurological
disorders such as depression55,56, stroke28, Parkinson’s
disease57, and chronic pain29. In a previous study, utilizing
depression models, Doucet et al. observed that the anti-
depressant effects of ZL006 was evident only after 24 and
72 h following treatment55. This delayed effect of the drug
on behavioral measures is also consistent with its
mechanism of action based on modifying neural plasticity.
Synaptic plasticity is a critical mechanism in both condi-
tioned fear memory and extinction. This series of studies
primarily focused on fear conditioning, but more future
studies are needed to elucidate about the role of PSD95-
nNOS interaction in extinction learning and extinction
memory retrieval. In addition, we need to better under-
stand if ZL006 effects confined to specific type of asso-
ciative learning and plasticity or if it broadly pro-
cognitive. If ZL006 inhibits plasticity too broadly, it
could impair extinction memory given its inhibitory
effects on plasticity. From our preliminary data in audi-
tory fear conditioning, there appears to be little increase
PSD95-nNOS interactions in the prefrontal cortex within
1–2 h after fear conditioning, and chronic treatment with
Fig. 5 Intra-amygdala infusion of ZL006 impairs memory formation of auditory fear conditioning. a Schematic of the behavioral protocol.
Rats were given intra-BLA infusion of ACSF (n= 10) or 10 µM ZL006 (n= 9) immediately after fear conditioning and the retention of conditioned fear
memory was tested 24 h later. b Both pre-assigned vehicle and ZL006 groups of animals showed normal cued fear acquisition (Trial: F2, 34= 308.8, P
< 0.0001). c Animals treated with ZL006 showed significantly reduced freezing responses in the fear expression test (Treatment: F1, 17= 4.974, P <
0.05). *P < 0.05 relative to vehicle
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ZL006 does not appear to disrupt learning in spatial
memory or source memory tests49. Thus, we predict that
it would most efficacious in weakening fear associations
and unlikely to interfere with safety learning. Future
studies will need to test these concepts in detail.
In summary, our present work shows that disrupting
PSD95/nNOS interaction with the small molecule ZL006
prevents the fear-conditioning-induced increase in
PSD95/nNOS interaction within the amygdala, impairs
LTP in amygdala neurons and attenuates the consolida-
tion of fear memory. Importantly, unlike NMDAR
antagonists, systemic ZL006 is devoid of effects on loco-
motor activity, and acute effects on learning and memory,
indicating that disrupting PSD95/nNOS interaction
represents a novel therapeutic approach for reducing
learned fear without eliciting adverse effects. Future stu-
dies will investigate the molecular and cellular mechan-
isms underlying ZL006 action and support the
development of PSD95/nNOS interaction based treat-
ment approach for fear-related disorders such as PTSD.
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